Table 1 Patient characteristics by treatment group

From: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study

  Interferon Observation
  (n=149) (n=149)
Median (range) age at diagnosis (years) 58 (31–76) 57 (33–78)
FIGO stage at diagnosis   
 I 11 (7%) 12 (8%)
 II 22 (14%) 19 (13%)
 III 94 (63%) 95 (64%)
 IV 22 (15%) 23 (15%)
Residual disease following surgery (cm)   
 0 23 (18%) 26 (20%)
 <2 44 (35%) 51 (40%)
 2–5 24 (19%) 13 (10%)
 >5 36 (28%) 40 (31%)
Histology   
 Serous 67 (45%) 72 (48%)
 Mucinous 10 (7%) 12 (8%)
 Endometrioid 27 (18%) 34 (23%)
 Clear cell 4 (3%) 4 (3%)
 Other 20 (13%) 10 (7%)
 Undifferentiated 3 (2%) 2 (1%)
 Not stated 18 (12%) 15 (10%)
Tumour grade   
 1 11 (9%) 14 (11%)
 2 47 (38%) 43 (33%)
 3 66 (53%) 75 (57%)
 Not stated 25 17
WHO performance status pre-chemotherapy   
 0 84 (60%) 83 (56%)
 1 46 (32%) 46 (31%)
 2 7 (4%) 17 (12%)
 3 3 (2%) 1 (1%)
 4 3 (2%) 0
 Not stated 6 2
Chemotherapy regimen   
 Platinum single agent 89 (60%) 88 (59%)
 Platinum combination 44 (29%) 37 (25%)
 Platinum/taxane 15 (10%) 20 (13%)
 Taxane single agent 0 1 (1%)
 Other single agent 1 (1%) 3 (2%)
Response to surgery and/or chemotherapy   
 Disease free 89 (61%) 95 (65%)
 Disease present 58 (39%) 52 (35%)
 Not evaluable 2 2
CA125 after surgery and/or chemotherapy   
 <35 U ml−1 47 (77%) 62 (78%)
 35–65 U ml−1 2 (3%) 9 (11%)
 65–200 U ml−1 8 (13%) 5 (6%)
 >200 4 (7%) 4 (5%)
 Not stated 88 69
WHO performance status at randomisation   
 0 113 (76%) 114 (79%)
 1 32 (22%) 28 (19%)
 2 3 (2%) 2 (1%)
 3 0 0
 4 0 0
 Not stated 1 5